
Kenneth G Walton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7402640/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Transcriptomics of Long-Term Meditation Practice: Evidence for Prevention or Reversal of Stress Effects Harmful to Health. Medicina (Lithuania), 2021, 57, 218.	2.0	7
2	Cardiovascular disease prevention and health promotion with the transcendental meditation program and Maharishi consciousness-based health care. Ethnicity and Disease, 2006, 16, S4-15-26.	2.3	12
3	Psychosocial Stress and Cardiovascular Disease Part 3: Clinical and Policy Implications of Research on the Transcendental Meditation Program. Behavioral Medicine, 2005, 30, 173-184.	1.9	19
4	Lowering Cortisol and CVD Risk in Postmenopausal Women: A Pilot Study Using the Transcendental Meditation Program. Annals of the New York Academy of Sciences, 2004, 1032, 211-215.	3.8	47
5	Review of Controlled Research on the Transcendental Meditation Program and Cardiovascular Disease. Cardiology in Review, 2004, 12, 262-266.	1.4	82
6	Effects of theTranscendental MeditationProgram on Neuroendocrine Abnormalities Associated with Aggression and Crime. Journal of Offender Rehabilitation, 2003, 36, 67-87.	0.8	11
7	Walpole Study of theTranscendental MeditationProgram in Maximum Security Prisoners III. Journal of Offender Rehabilitation, 2003, 36, 161-180.	0.8	26
8	Walpole Study of theTranscendental MeditationProgram in Maximum Security Prisoners I. Journal of Offender Rehabilitation, 2003, 36, 97-125.	0.8	18
9	TheTranscendental MeditationProgram. Journal of Offender Rehabilitation, 2003, 36, 1-33.	0.8	3
10	Consciousness-BasedRehabilitation of Inmates in the Netherlands Antilles. Journal of Offender Rehabilitation, 2003, 36, 205-228.	0.8	5
11	Psychosocial Stress and Cardiovascular Disease: Pathophysiological Links. Behavioral Medicine, 2002, 27, 141-147.	1.9	137
12	Psychosocial Stress and Cardiovascular Disease Part 2: Effectiveness of the <i>Transcendental Meditation</i> Program in Treatment and Prevention. Behavioral Medicine, 2002, 28, 106-123.	1.9	69
13	Effect of a multimodality natural medicine program on carotid atherosclerosis in older subjects: a pilot trial of Maharishi Vedic Medicine. American Journal of Cardiology, 2002, 89, 952-958.	1.6	67
14	All Approaches to Preventing or Reversing Effects of Stress are Not the Same. American Journal of Health Promotion, 1998, 12, 297-299.	1.7	56
15	A Controlled Study of the Effects of the Transcendental Meditation® Program on Cardiovascular Reactivity and Ambulatory Blood Pressure. International Journal of Neuroscience, 1997, 89, 15-28.	1.6	116
16	Anger Expression Correlates With Platelet Aggregation. Behavioral Medicine, 1997, 22, 174-177.	1.9	24
17	Effects of the transcendental meditation program on adaptive mechanisms: Changes in hormone levels and responses to stress after 4 months of practice. Psychoneuroendocrinology, 1997, 22, 277-295.	2.7	192
18	The Impact of the Transcendental Meditation Program on Government Payments to Physicians in Quebec. American Journal of Health Promotion, 1996, 10, 208-216.	1.7	26

KENNETH G WALTON

#	Article	IF	CITATIONS
19	Trial of Stress Reduction for Hypertension in Older African Americans. Hypertension, 1996, 28, 228-237.	2.7	111
20	Stress Reduction and Preventing Hypertension: Preliminary Support for a Psychoneuroendocrine Mechanism. Journal of Alternative and Complementary Medicine, 1995, 1, 263-283.	2.1	136
21	Importance of Reducing Stress and Strengthening the Host in Drug Detoxification:. Alcoholism Treatment Quarterly, 1994, 11, 297-331.	0.8	3
22	Effectiveness of Broad Spectrum Approaches to Relapse Prevention in Severe Alcoholism:. Alcoholism Treatment Quarterly, 1994, 11, 187-220.	0.8	41
23	A Neurondocrine Mechanism for the Reduction of Drug Use and Addictions by Transcendental Meditiation. Alcoholism Treatment Quarterly, 1994, 11, 89-117.	0.8	15
24	Effectiveness of the Transcendental Meditation Program in Preventing and Treating Substance Misuse: A Review. Substance Use and Misuse, 1991, 26, 293-325.	0.6	71
25	Beta-adrenergic receptor sensitivity in subjects practicing transcendental meditation. Journal of Psychosomatic Research, 1990, 34, 29-33.	2.6	51
26	The noradrenergic system in cultured aggregates of fetal rat brain cells: Morphology of the aggregates and pharmacological indices of noradrenergic neurons. Brain Research, 1981, 230, 235-252.	2.2	11
27	Effects of isoproterenol on the development of β-adrenergic receptors in brain cell aggregates. Brain Research, 1981, 207, 174-177.	2.2	14
28	Effects of alternative transmitter amines on cyclic AMP formation in rat brain tissue. European Journal of Pharmacology, 1979, 56, 167-171.	3.5	4
29	Prenatal and early postnatal β-adrenergic receptor-mediated increase of cyclic AMP in slices of rat brain. Brain Research, 1979, 177, 515-522.	2.2	22
30	Inhibition of dopamine-stimulated adenylate cyclase activity by phenoxybenzamine. European Journal of Pharmacology, 1978, 52, 231-234.	3.5	35
31	Hydrolysis of diester prodrugs of apomorphine. Biochemical Pharmacology, 1977, 26, 1749-1756.	4.4	23
32	Behavioral effects of apomorphine and diisobutyrylapomorphine in the mouse. Psychopharmacology, 1977, 53, 45-53.	3.1	31
33	Diester derivatives as apomorphine prodrugs. Journal of Medicinal Chemistry, 1976, 19, 717-719.	6.4	30
34	Prolonged storage of mitochondria by freezing: Retention of respiratory control and energized swelling. Journal of Bioenergetics and Biomembranes, 1970, 1, 3-8.	2.3	9
35	Control of mitochondrial swelling by Mg2+?the relation of ion transport to structural changes. Journal of Bioenergetics and Biomembranes, 1970, 1, 247-271.	2.3	13